PHILADELPHIA and BALTIMORE, Sept. 03, 2020 (GLOBE NEWSWIRE) -- WindMIL Therapeutics, a clinical-stage company developing marrow-infiltrating lymphocyte (MILs™) products for cancer immunotherapy, today announced that Chairman and Chief Executive Officer Don Hayden will present a corporate overview at Citi's 15th Annual BioPharma Virtual Conference on Thursday, September 8, 2020 at 4:05 pm EDT.
About WindMIL Therapeutics
WindMIL Therapeutics is a clinical-stage company developing a novel class of autologous cell therapies based on marrow-infiltrating lymphocytes (MILs™) for cancer immunotherapy. As the leader in bone marrow-derived T cell therapies, WindMIL translates novel insights in bone marrow immunology into life-saving cancer immunotherapeutics for patients. The company’s proprietary process to activate, transform and expand T cells offers unique immunotherapeutic advantages, including inherent tumor-specificity, high cytotoxic potential and long persistence. For more information, please visit: https://windmiltx.com.
WindMIL Therapeutics Media Contact:
Gina Cestari
6 Degrees
(917) 797-7904
gcestari@6degreespr.com